The global fecal calprotectin test market is experiencing significant expansion, driven by the increasing prevalence of inflammatory bowel diseases (IBD) and the growing demand for non-invasive diagnostic tools. The market is projected to witness strong growth during the forecast period from 2025 to 2032.

The global fecal calprotectin test market size was valued at USD 2,865.3 million in 2024 and is projected to grow from USD 3,026.2 million in 2025 to USD 4,687.1 million by 2032, exhibiting a CAGR of 6.45% during the forecast period.

Market Overview

• Current Market Size: Significant and growing globally
• Projected Market Size: Expected to increase considerably by 2032
• CAGR: Moderate to high growth expected during 2025–2032

Key Market Drivers

• Rising Incidence of IBD: The increasing prevalence of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, is a primary factor driving the demand for fecal calprotectin testing.
• Non-Invasive Diagnostic Preference: Patients and healthcare providers are increasingly opting for non-invasive diagnostic methods, making fecal calprotectin tests a preferred choice.
• Advancements in Diagnostic Technologies: Technological innovations in assay sensitivity and automation are enhancing the accuracy and efficiency of fecal calprotectin tests.

Unlock Key Growth Opportunities: https://www.kingsresearch.com/fecal-calprotectin-test-market-368

List of Key Companies in Fecal Calprotectin Test Market:

• ALPCO
• ORGENTEC Diagnostika
• EagleBio
• F. Hoffmann-La Roche Ltd
• Alpha Laboratories
• DiaSorin S.p.A.
• Immundiagnostik AG
• BÜHLMANN
• Epitope Diagnostics, Inc.
• Thermo Fisher Scientific Inc.
• Biohit Oyj
• Svar Life Science AB
• Abbott
• DRG INSTRUMENTS GMBH
• Sysmex Corporation

Market Segmentation

• By Assay Type:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Enzyme Fluoroimmunoassay
  • Quantitative Immunochromatography
• By Indication:
  • Inflammatory Bowel Disease (IBD)
  • Colorectal Cancer
  • Celiac Disease
• By End-User:
  • Diagnostic Laboratories
  • Hospitals
  • Academic & Research Institutes

Regional Analysis

• North America:
  • Market share is significant in the region
  • Growth is supported by advanced healthcare infrastructure and high disease prevalence
• Asia Pacific:
  • Expected to witness strong growth over the forecast period
  • Expansion driven by improving healthcare infrastructure and increasing awareness about gastrointestinal diseases
• Europe, Latin America, and Middle East & Africa:
  • Growth driven by rising prevalence of IBD, increasing healthcare expenditure, and adoption of non-invasive diagnostics

Future Outlook

The fecal calprotectin test market is expected to continue its upward trajectory, driven by technological advancements, increasing disease prevalence, and the rising preference for non-invasive diagnostic methods. Key players are likely to focus on expanding their product portfolios and enhancing diagnostic capabilities to meet the growing global demand.

About Kings Research

Kings Research is a leading market research and consulting firm providing actionable insights and strategic recommendations to businesses across various industries. Their comprehensive research methodology helps clients make informed decisions and achieve sustainable growth.